Allogeneic stem cell transplantation (ASCT) from related or unrelated donors may cure patients with myelodysplastic syndromes (MDS), a heterogeneous group of clonal stem cell disorders. We analysed 384 elderly patients (55-69 years) with advanced MDS who received either ASCT (n=247) and were reported to The European Group for Blood and Marrow Transplantation (EBMT) or a non -transplant approach (n=137) reported to the Düsseldorf registry. Besides an attempt to answer the question of "comparison", the purpose of this work is to explain the difficulties in comparing a non-transplant with a transplant cohort, when death before transplant is likely but unknown and the selection of patients for transplant is based on assumptions. It shows which ...
In this study, we compared transplantation outcomes of allogeneic hematopoietic stem cell transplant...
In this retrospective analysis we evaluated the outcome of 313 patients aged >= 70 years in the regi...
We investigated whether a young human leukocyte antigen (HLA)-matched unrelated donor (MUD) should b...
Allogeneic stem cell transplantation (ASCT) from related or unrelated donors may cure patients with ...
Allogeneic stem cell transplantation (ASCT) from related or unrelated donors may cure patients with ...
Contains fulltext : 183575.PDF (publisher's version ) (Open Access)Allogeneic stem...
Purpose This study was performed to examine the characteristics of transplant activity for patients ...
Myelodysplastic syndromes are clonal disorders with morphological dysplasia, a variable degree of cy...
PURPOSE: Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders that are more common ...
In this retrospective analysis we evaluated the outcome of 313 patients aged ≥ 70 years in the regis...
PURPOSE: This study was performed to examine the characteristics of transplant activity for patients...
PURPOSE In contrast to 5-azacytidine (5-aza), allogeneic stem-cell transplantation (HSCT) represents...
Item does not contain fulltextIn this retrospective analysis we evaluated the outcome of 313 patient...
Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative treatment...
Allogeneic stem cell transplantation (alloSCT) is the treatment of choice in the majority of young p...
In this study, we compared transplantation outcomes of allogeneic hematopoietic stem cell transplant...
In this retrospective analysis we evaluated the outcome of 313 patients aged >= 70 years in the regi...
We investigated whether a young human leukocyte antigen (HLA)-matched unrelated donor (MUD) should b...
Allogeneic stem cell transplantation (ASCT) from related or unrelated donors may cure patients with ...
Allogeneic stem cell transplantation (ASCT) from related or unrelated donors may cure patients with ...
Contains fulltext : 183575.PDF (publisher's version ) (Open Access)Allogeneic stem...
Purpose This study was performed to examine the characteristics of transplant activity for patients ...
Myelodysplastic syndromes are clonal disorders with morphological dysplasia, a variable degree of cy...
PURPOSE: Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders that are more common ...
In this retrospective analysis we evaluated the outcome of 313 patients aged ≥ 70 years in the regis...
PURPOSE: This study was performed to examine the characteristics of transplant activity for patients...
PURPOSE In contrast to 5-azacytidine (5-aza), allogeneic stem-cell transplantation (HSCT) represents...
Item does not contain fulltextIn this retrospective analysis we evaluated the outcome of 313 patient...
Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative treatment...
Allogeneic stem cell transplantation (alloSCT) is the treatment of choice in the majority of young p...
In this study, we compared transplantation outcomes of allogeneic hematopoietic stem cell transplant...
In this retrospective analysis we evaluated the outcome of 313 patients aged >= 70 years in the regi...
We investigated whether a young human leukocyte antigen (HLA)-matched unrelated donor (MUD) should b...